.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Citi
Chubb
Express Scripts
Teva
McKinsey
UBS
Covington
Cantor Fitzgerald
Johnson and Johnson

Generated: November 18, 2017

DrugPatentWatch Database Preview

Hoffmann La Roche Company Profile

« Back to Dashboard

What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?

HOFFMANN LA ROCHE has fourteen approved drugs.

There are fourteen US patents protecting HOFFMANN LA ROCHE drugs.

There are four hundred and seventeen patent family members on HOFFMANN LA ROCHE drugs in fifty-two countries and twenty-eight supplementary protection certificates in fifteen countries.

Summary for Hoffmann La Roche

International Patents:417
US Patents:14
Tradenames:12
Ingredients:11
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
ROCEPHIN
ceftriaxone sodium
INJECTABLE;INJECTION063239-001Aug 13, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ROCEPHIN
ceftriaxone sodium
INJECTABLE;INJECTION062654-001Apr 30, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ROCEPHIN
ceftriaxone sodium
INJECTABLE;INJECTION063239-003Aug 13, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ROCEPHIN
ceftriaxone sodium
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS050585-003Dec 21, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-002Mar 24, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-002Mar 24, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Hoffmann La Roche
FORTOVASE
saquinavir
CAPSULE;ORAL020828-001Nov 7, 1997DISCNYesNo► Subscribe► SubscribeY► Subscribe
Hoffmann La Roche
ROCEPHIN KIT
ceftriaxone sodium; lidocaine
INJECTABLE;INJECTION050585-006May 8, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
ceftriaxone sodium
INJECTABLE;INJECTION050624-001Feb 11, 1987DISCNYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-003May 7, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-001May 16, 2003► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-003May 7, 1982► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-003May 7, 1982► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-002May 7, 1982► Subscribe► Subscribe
Hoffmann La Roche
VALCYTE
valganciclovir hydrochloride
TABLET;ORAL021304-001Mar 29, 2001► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-004Mar 28, 1983► Subscribe► Subscribe
Hoffmann La Roche
FORTOVASE
saquinavir
CAPSULE;ORAL020828-001Nov 7, 1997► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998► Subscribe► Subscribe
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-002Mar 24, 2005► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-003May 7, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for HOFFMANN LA ROCHE drugs

Drugname Dosage Strength Tradename Submissiondate
valganciclovir hydrochloride
For Oral Solution50 mg/mL
VALCYTE
3/21/2011
capecitabine
Tablets150 mg and 500 mg
XELODA
11/10/2008
ibandronate sodium
Injection1 mg/mL, 3 mL Vial
BONIVA
8/31/2007
ibandronate sodium
Tablets2.5 mg and 150 mg
BONIVA
5/16/2007
valganciclovir hydrochloride
Tablets450 mg
VALCYTE
12/27/2005

Premature patent expirations for HOFFMANN LA ROCHE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Hoffmann La Roche

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,627,221 Pharmaceutical composition containing diphosphonic acid or salt thereof► Subscribe
8,415,469Compounds and methods for kinase modulation, and indications therefor► Subscribe
8,530,661Process for the manufacture of pharmaceutically active compounds► Subscribe
8,889,109Pharmaceutical dosage forms comprising valganciclovir hydrochloride► Subscribe
7,846,941Compounds modulating c-kit and c-fms activity and uses therefor► Subscribe
8,067,434Compounds and methods for development of Ret modulators► Subscribe
9,663,517Compositions and uses thereof► Subscribe
8,329,724Process for the manufacture of pharmaceutically active compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hoffmann La Roche Drugs

Country Document Number Estimated Expiration
Argentina039978► Subscribe
Russian Federation2629999► Subscribe
EcuadorSP088121► Subscribe
Yugoslavia20501► Subscribe
Spain2253919► Subscribe
Spain2313735► Subscribe
World Intellectual Property Organization (WIPO)2011015522► Subscribe
Cyprus1118328► Subscribe
Argentina078033► Subscribe
China100551377► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hoffmann La Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/025Ireland► SubscribePRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
00071Netherlands► SubscribePRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
2012010,C1893612Lithuania► SubscribePRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
C/GB12/021United Kingdom► SubscribePRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/12/751/001 20120221
2012000043Germany► SubscribePRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
C/GB98/044United Kingdom► SubscribePRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
00045Netherlands► SubscribePRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610
C0042Belgium► SubscribePRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
01C/021Belgium► SubscribePRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Deloitte
Medtronic
Citi
Boehringer Ingelheim
Dow
Queensland Health
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot